Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be held in New York City, September 14th -16th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
Presentation Details:
|
H.C. Wainwright 28th Annual Global Investment Conference | |
| Company Presentation: | September 15, 2026 |
| Time: | 1:30 PM ET |
| Location: | New York, NY |
| Webcast Link: | Company Presentation |
The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please reach out to your institutional contact at H.C. Wainwright.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries:
media@sperotx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
